Skolkovo startup gets investment to test cure for HIV
Advanced Gene & Cell Technologies (AGCT), a resident startup of the Skolkovo Foundation’s biomed cluster, has received the first tranche of investment from the RBV Capital venture fund allocated to carry out Russia’s first clinical practice of genome editing to treat HIV. AGCT plans to use the investment, which totals 44 million rubles ($738,000), to draw up a raft of preclinical data to carry out pilot phase one and two clinical research.
